Consumption of salmon fishmeal increases hepatic cholesterol content in obese C57BL/6 J mice

Marit Hjorth · Atanaska Doncheva · Frode Norheim · Stine Marie Ulven · Kirsten Bjørklund Holven · Thomas Sæther · Knut Tomas Dalen

Received: 2 February 2022 / Accepted: 31 May 2022 / Published online: 5 July 2022
© The Author(s) 2022

Abstract

Purpose By-products from farmed fish contain large amounts of proteins and may be used for human consumption. The purpose of this study was to investigate cardiometabolic effects and metabolic tolerance in mice consuming fishmeal from salmon by-products, salmon filet or beef.

Methods Female C57BL/6J mice were fed chow, as a healthy reference group, or a high-fat diet for 10 weeks to induce obesity and glucose intolerance. Obese mice were subsequently given isocaloric diets containing 50% of the dietary protein from salmon fishmeal, salmon filet or beef for 10 weeks. Mice were subjected to metabolic phenotyping, which included measurements of body composition, energy metabolism in metabolic cages and glucose tolerance. Lipid content and markers of hepatic toxicity were determined in plasma and liver. Hepatic gene and protein expression was determined with RNA sequencing and immunoblotting.

Results Mice fed fishmeal, salmon filet or beef had similar food intake, energy consumption, body weight gain, adiposity, glucose tolerance and circulating levels of lipids and hepatic toxicity markers, such as p-ALT and p-AST. Fishmeal increased hepatic cholesterol levels by 35–36% as compared to salmon filet (p = 0.0001) and beef (p = 0.005). This was accompanied by repressed expression of genes involved in steroid and cholesterol metabolism and reduced levels of circulating Pcsk9.

Conclusion Salmon fishmeal was well tolerated, but increased hepatic cholesterol content. The high cholesterol content in fishmeal may be responsible for the effects on hepatic cholesterol metabolism. Before introducing fishmeal from salmon by-products as a dietary component, it may be advantageous to reduce the cholesterol content in fishmeal.

Keywords Salmon · Fishmeal · Liver · Cholesterol · Glucose tolerance · RNA sequencing · Pcsk9 · Salmon by-products · Fish protein

Abbreviations

Hmgcr 3-Hydroxy-3-methylglutaryl coenzyme A reductase
ALT Alanine transaminase
AST Aspartate transaminase
DHA Docosahexaenoic acid
EPA Eicosapentaenoic acid
FA Fatty acids
GTT Glucose tolerance testing
HFD High-fat diet
Ldr Low-density lipoprotein receptor
MUFA Monounsaturated fatty acids
PPARs Peroxisome proliferator-activated receptors
PUFA Polyunsaturated fatty acids
Pcsk9 Proprotein convertase subtilisin/kexin 9
SFA Saturated fatty acids
SREBPs Sterol regulatory element binding proteins
Tbp Tata-binding protein
Introduction

A constantly increasing world population creates higher demands on food production and requires improved agricultural and aquacultural sustainability and efficiency [1]. This necessitates exploring potential use of food resources that are available but not used for human consumption. One such resource is by-products from fish [2, 3]. In Norway, one of the largest fishery nations in the world, around 27% of produced fish and seafood are discarded from human consumption and classified as by-products [4]. Farmed salmon by-products contain large amounts of proteins and other nutrients, and may serve as a significant food source of human nutrition [2, 3].

Fish has high content of protein and fatty acids (FAs), as well as several nutrients, such as vitamin D, iodine, selenium and taurine that are less abundant in many types of food typically consumed by humans. Compared to available food alternatives, fish products are particularly attractive for human consumption since intake of fish is associated with reduced risk of cardiovascular disease and may also protect against metabolic syndrome [5, 6]. These beneficial health effects are in part caused by a high content of marine n-3 polyunsaturated fatty acids (PUFA), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) with anti-inflammatory properties (reviewed in [7]). EPA and DHA can also affect membrane fluidity, thereby influencing lipid raft assembly and inflammatory signal transduction [7]. Furthermore, dietary FAs can modulate lipid metabolism by controlling transcription factors, such as peroxisome proliferator-activated receptors (PPARs) and sterol regulatory element binding proteins (SREBPs) [8, 9]. Marine n-3 PUFAs can suppress FA synthesis in liver via reduced SREBP-1c activity and increase FA oxidation via activation of PPARs and upregulation of FA-oxidizing enzymes. Due to these metabolic effects, intake of marine n-3 FAs can decrease hepatic lipid accumulation, VLDL secretion and plasma triglyceride levels.

While many studies support that consumption of marine FAs have beneficial metabolic effects in humans, the potential beneficial effects of fish protein consumption is less explored. Growing evidence is suggesting that the source of dietary proteins similarly can influence health and longevity in humans [10–13]. A high intake of animal protein, when compared against plant protein, has been associated with increased morbidity or mortality in several studies [10–13]. Furthermore, proteins from fish may have beneficial effects on metabolic health [14]. In a human intervention study, intake of dietary cod protein associated with increased insulin sensitivity [15]. In another intervention on overweight individuals, even a modest daily intake of a fish protein supplement (3–6 g) tended to improve glucose tolerance and LDL cholesterol [16]. In rodents, several studies have reported that salmon protein hydrolysates can improve glucose regulation, reduce body weight gain and modulate hepatic lipid metabolism [17–19].

We recently conducted a randomized, controlled trial on 74 human participants to investigate effects of 8 weeks supplementation with fishmeal from salmon by-products [20]. Daily supplementation with 7.5 g of fishmeal, corresponding to 5.2 g of salmon protein, did not influence cardiometabolic risk factors, such as glucose tolerance, serum lipids or blood pressure in humans. In the current study, the objective was to investigate metabolic effects of a high intake of fishmeal in obese mice. To investigate the effects of fishmeal feeding, compared to feeding with salmon filet or beef, obese C57BL/6 J mice were fed for 10 weeks with high-fat diets formulated with half of the protein content from these alternative protein sources.

Materials and methods

Ethical considerations and animal housing conditions

Experimental use of animals was approved by the Norwegian Animal Research Authority (Mattilsynet, approvals FOTS id: #10,902) and conformed to the ARRIVE guidelines and ethical guidelines in Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. Mice were housed with a 12 h light/dark cycle (7 am to 7 pm), with 55% relative humidity at 22 °C, with free access to water and food. The presence of pathogens was monitored quarterly according to the FELASA guidelines (Federation of European Laboratory Animal Science Associations). Animals were specific pathogen-free according to FELASA recommendations (SPF status). A total of 40 mice were included in this study and no mice were excluded from the analyses.

Preparation and nutritional composition analysis of freeze-dried ingredients

High-quality salmon fishmeal was produced from by-products of farmed Atlantic salmon, such as heads, viscera and spines (Mowi ASA, Bergen, Norway). Salmon filet from back loin (salmon filet) and entrecote of beef (beef) were freeze-dried in house (LyoQuest, Telestar, Spain) and ground in a regular kitchen mixer. Amino acid content (Supplemental Tables S1) and micronutrient content (Supplemental Tables S2) in fishmeal, salmon filet and beef were measured by Eurofins Food & Feed Testing Norway AS.
FA composition in fishmeal, salmon filet and beef was measured by VITAS analytical services (Forskningsparken, Norway); freeze-dried samples were weighed and transferred to soda lime tubes. Internal standard, methyl tricosanoate and 3 N Methanolic HCl were added and FAs methylated for 2 h at 80 °C prior to analysis. 100 µl prepared sample was transferred to GC vial, diluted with hexane and injected on an Agilent 7890A Gas Chromatograph System (Agilent Technologies). FAs were separated on a Supelcowax (30 m ×250 µm ×0.2 µm) column.

Mouse diet intervention

Female C57BL6/J mice (8 weeks, Janvier Labs) were fed a chow diet with 11 E% from fat, 62 E% from carbohydrates and 26 E% from protein (Special Diets Service, UK, #RM3) or a high-fat diet (HFD) with 60 E% from fat, 20 E% from carbohydrates and 20 E% from protein (Research diets, cat#D12492) for 10 weeks. From 18 to 28 weeks of age, chow-fed mice continued on the chow diet, while the HFD-fed mice were split into three groups and given alternative HFDs that differed in their sources of protein (Table 1, Fig. 1); fishmeal extracted from salmon by-products (Mowi ASA; fishmeal); salmon filet from back loin (salmon filet) or entrecote of beef (beef). The alternative diets were generated by modifying the HFD into a basis diet lacking 10 E% protein from casein (Research diets, cat#D19020401), which were supplemented with 10 E% protein from freeze-dried fishmeal, salmon filet or beef (Table 1). Soybean oil was added to adjust for differences in fat content in the freeze-dried protein sources (Table 1) to generate isocaloric diets with the same amounts of carbohydrates, protein and fat (Table 2). The three diets were mixed in a regular kitchen mixer, sterilized by autoclaving, formed into pellets by hand and stored at −20 °C until use. The drinking water was supplemented with multivitamin drops (Vitamin A, D3, E, K3 and B-vitamin complex) for rodents.

At 28 weeks of age, mice were sedated by isoflurane inhalation and blood was collected by cardiac puncture with an EDTA-coated syringe. This was followed by cervical dislocation and rapid collection of tissues. Tissues were snap frozen in liquid nitrogen. Plasma was obtained by separating out blood cells with gentle centrifugation.

Metabolic phenotyping, GTT and body composition measurements

Body composition measurements were performed at multiple time points with a Minispec LF90II TD-NMR machine (Bruker, Billerica, MA, USA). Body weight was measured weekly. Food intake was measured by weighing food consumed in each cage at 16 individual time points.

At 25 weeks of age, mice were placed in a metabolic cage system consisting of 20 individual cages (Phenomaster, TSE Systems, Germany) for 3 days. For indirect calorimetric measurement of gas exchange (oxygen consumption and carbon dioxide production), we used the following settings: gas flow rate at 0.42 l/minute, measurement time for 10 s, and gas exchange measurement in 20 min intervals. Physical activity was measured as movement in the XY-plane. Body weight and composition were measured prior to metabolic phenotyping.

At 27 weeks of age, glucose tolerance testing (GTT) was performed. Mice were fasted for 5 h, starting at 08:00 am, and then injected (i.p) with 2 g glucose (20% glucose in saline) per kg lean mass. Blood samples were collected from the tip of the tail before glucose injection, and at 15, 30, 45,
60, 90 and 120 min after glucose injection. Glucose concentrations were measured in whole blood with a FreeStyle Precision Neo glucometer (Abbott, IL, US). Insulin concentrations were measured in 5 µl plasma with ELISA (Crystal Chem, cat# 90,080).

**Analyses of cholesterol, triglycerides, bile acids and liver enzymes**

Preparation of liver lysates: Liver tissue was homogenized in 5% NP40 in PBS by vigorous shaking with glass beads with Precellys 24 (Bertin Technologies, Rockville MD US) and then sonicated on high power mode for 2 cycles, 30 s on and 30 s off with a Bioruptor plus (Diagenode, Belgium). Protein concentrations in liver lysates were measured with a Pierce BCA assay (Thermo Fisher Scientific, Waltham, MA US).

Triglycerides and total cholesterol in liver lysates and plasma were measured with colorimetric reagent sets (Pointe Scientific, Canton, MI, US, Cat# T7532 and Cat# C7510). HDL and LDL/VLDL cholesterol in plasma were measured with a colorimetric kit (Abcam, cat# ab65390). Plasma concentrations of alanine transaminase (ALT) and aspartate transaminase (AST) were measured with colorimetric MedTest reagent sets (Pointe Scientific, Canton, MI, US, Cat# A7561/Cat# A7526).

Bile acids were measured in plasma, liver and faeces with a total bile acids kit for mouse (Crystal Chem, cat# 80,470). Faeces was collected from individually housed mice and air-dried for 4 days. Liver and faeces samples were homogenized in 75% ethanol in water by vigorous shaking with glass beads (Precellys 24, Bertin Technologies, Montigny-le-Bretonneux, France). They were then incubated for 2 h at 50 °C in glass tubes and centrifuged (10 min, 6000 g, 4 °C).

**RNA isolation, reverse transcription and quantitative PCR**

Liver tissue was homogenized in RA1 lysis buffer by vigorous shaking with glass beads (Precellys 24, Bertin Technologies, Montigny-le-Bretonneux, France). RNA was subsequently isolated using a NucleoSpin RNA isolation kit (Macherey–Nagel, Allentown, PA, US), with a modified pre-preparation method prior to loading on the RNA-binding columns [21]. RNA purity and concentration was measured on a NanoDrop ND-100 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA US).

Reverse transcription (RT) of RNA. Total RNA was reversely transcribed with random hexamers using a High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA US, Cat. #4,368,814) on an ep Gradient S Eppendorf Mastercycler (Eppendorf AG, Hamburg, Germany) with the following settings: 25 °C for 10 min, 37 °C for 120 min, 85 °C for 5 min and 4 °C on hold.

qPCR with fluorescent intercalating dye. Gene-specific regions were amplified from cDNA with assay primers (200 nmol/L each) and Bio-Rad SsoAdvanced™ Universal SYBR® Green Supermix (10 µL reaction, 95 °C for 3 min, followed by 40 cycles of 95 °C for 10 s and 60 °C for 20 s) on a CFX96 Touch instrument (Bio-Rad). Primers used were designed with Primer-BLAST (Supplemental Table S3). Gene expression was calculated using the 2−ΔΔCt method. Tbp mRNA was verified to be stably expressed among groups and treatments, and was used as a reference gene.
RNA sequencing and data analysis

RNA integrity was determined using Bioanalyzer RNA 6000 Nano (Agilent Technologies), according to the manufacturer’s instruction. The RNA samples had RIN values between 8.1 and 8.7. Samples were sequenced at the Norwegian Sequencing Centre (Oslo University Hospital, Ullevål, Oslo). Total RNA samples were subjected to Strand-Specific TruSeq™ mRNA-seq library preparation, and 50 bp paired-end reads were sequenced on an Illumina Novaseq 600 instrument. To remove/trim low-quality reads and adapter sequences we used BBduk (BBMap v34.56 [22]). Reads were mapped to the Mus musculus reference genome (ENSEMBL release 101, GRCh38.101) using HiSat2 v1.2.1 [23]. Read counting was done with FeatureCounts v1.4.6-p1 [24]. The average read count was 40 million/sample. Raw sequencing data and normalized counts are available in the GEO repository (GSE188546).

Immunoblotting

Liver tissue was lysed in RIPA buffer containing complete EDTA-free Protease Inhibitor Cocktail (Cat. #11,836,170,001, Roche, Basel, Switzerland) and phosphatase inhibitors (Cat. #P0044, Sigma-Aldrich, St. Louis, MO, US). Samples were homogenized using glass beads and a Precellys 24 tissue homogenizer (Bertin Instruments, Montigny-le-Bretonneux, France) and sonicated on a Bioruptor® Plus device (Diagenode, Liege, Belgium). Lysates were diluted in Laemmli buffer, proteins separated on Criterion™ TGX™ 4–20% gels (Bio-Rad, Hercules, CA, US), and transferred to nitrocellulose membranes using the Trans-Blot Turbo transfer system and RTA transfer kit (Bio-Rad, Hercules, CA, US). Membranes were stained with Ponceau S to confirm similar total protein loaded in each lane. Membranes were blocked in Tris-buffered saline containing 0.1% Tween-20 (TBS-T) and 5% BSA and incubated overnight with primary antibodies in TBS-T containing 2.5% BSA. After washing, membranes were incubated with appropriate HRP-conjugated secondary antibodies. Primary antibodies used were as follows: Goat anti-Ldlr (#AF2255, R&D Systems), goat anti-Pcsk9 (#AF3985, R&D Systems, Minneapolis, MN, US), rabbit anti-Hmgcr (#PA5-37,367, Thermo Fisher Scientific, Waltham, MA US), and rabbit anti-Gapdh (#sc-25778, Santa-Cruz Biotechnology, Dallas, TX, US). Secondary antibodies used were as follows: Goat anti-rabbit IgG (#111–035-144), and bovine anti-goat IgG (#805–035-180; Jackson ImmunoResearch, West Grove, PA, US). Chemiluminescence detection was done on the ChemiDoc™ Touch Imaging System (BioRad, Hercules, CA, US). Band intensities were quantified relative to Gapdh signals using ImageJ v1.52 software (NIH, Bethesda, MD, US).

Data analysis

For analyses of RNA sequencing counts we used R version 4.0.3. Differential expression analyses were done using the Deseq2 pipeline on background filtered read counts [25]. False discovery rate (fdr) < 0.05 was considered statistically significant. PCA plots were generated after variance-stabilizing transformation in Deseq2. Gene ontology analyses were done in the clusterProfiler package with KEGG pathway annotations [26]. For other analyses, we used Graphpad Prism software (version 8). Methods used for statistical testing are listed in the figure legends.

Results

Nutritional composition of diets supplemented with fishmeal, salmon or beef

To study the effects of fishmeal, salmon or beef intake in obese and glucose intolerant animals, 8-week-old female C57BL/6 J mice were first fed a high-fat diet (HFD, 60 E% from fat) for 10 weeks (Fig. 1). As expected, the HFD feeding led to increased body weights and fat mass (9.7 g fat mass, compared to 0.92 g in the chow group), as well as enhanced plasma blood glucose before and 1 h after intraperitoneal administration of glucose (Supplemental Fig. 1). The obese mice were then randomized to receive a HFD containing 50% of total protein from freeze-dried fishmeal, salmon filet or beef for 10 weeks (Fig. 1). To generate alternative HFDs diets that were isocaloric with equal amounts of carbohydrates, fat and protein, we first measured the content of macronutrients in each protein source. Freeze-dried fishmeal contained 69.7% protein, while salmon and beef contained 57.7% and 67.8% protein, respectively. Salmon filet contained more fat (40.8%) compared to fishmeal (13.2%) and beef (33.4%), while carbohydrate content was marginable (Table 1). Soybean oil was added to diets to adjust for differences in fat content in the alternative protein sources (Table 2). The remaining fat in the HFDs was mainly from lard, while carbohydrates were mainly from sucrose and maltodextrin.

We further performed detailed analyses of macro- and micronutrients in freeze-dried fishmeal, salmon filet and beef (Table 1, Supplementary Table S1-2, Fig. 2). As expected, a higher proportion of the FAs in beef were saturated FAs (SFA: 52%), compared to 15% SFA in salmon filet and 22% SFA in fishmeal. The amount of monounsaturated FAs (MUFA) was more similar, while in both fishmeal and salmon filet, approximately 30% of the fat was PUFAs (Fig. 2A). Salmon filet contained a higher amount of marine PUFAs (> C20), including DHA.
and EPA, compared to fishmeal and beef (Fig. 2c–d). Because freeze-dried salmon filet contained more fat than fishmeal and beef (see Table 1), salmon filet contained higher amounts of both MUFAs and PUFAs as compared to fishmeal and beef (Fig. 2c–d). FAs from freeze-dried material and the added soybean oil constituted ~28% of total fat in the final diets, while the rest of the fat was from lard. Although levels of SFAs, MUFAs and PUFAs were different in the three freeze-dried ingredients, the levels of these FAs in the final diets were more comparable (Table 2). Of other lipids, fishmeal contained higher levels of cholesterol (493 mg/100 g) compared to salmon filet (144 mg/100 g) and beef (190 mg/100 g; Table 1). This resulted in >2-fold higher content of total cholesterol in the fishmeal diet (Table 2).

Because different amino acids have different effects on liver metabolism, we compared the amino acid content of freeze-dried fishmeal, salmon filet and beef (Supplementary Table S1). Essential amino acid content was quite similar, with the exception of higher levels of histidine in beef. Fishmeal contained more glycine (5.1 g/100 g) compared to salmon filet (2.6 g/100 g) and beef (3.3 g/100 g). Fishmeal also contained more proline (3.2 g/100 g) than salmon filet and beef (2.0 and 2.7 g/100 g, respectively), as well as hydroxyproline (0.57 g/100 g). The latter being below limit of detection for salmon filet and beef. A higher content of glycine, proline and hydroxyproline is most likely originating from collagen in, e.g. connective tissue, a major part of salmon by-products.

Lastly, we measured the content of vitamins and minerals in salmon fishmeal (Supplementary Table S2) and compared against corresponding reference values for salmon filet and beef (Norwegian Food Composition Database [27]). Fishmeal contained high levels of vitamin B₂ (5.1 mg/100 g), vitamin B₁₂ (61 μg/100 g) and several minerals, particularly calcium (2500 mg/100 g), zinc (140 mg/100 g), copper (8.6 mg/100 g) and iodine (0.17 mg/100 g). The high content of copper and zinc in fishmeal leads to intake levels of these minerals above the recommended upper limit for human consumption (calculated as mg/kg body weight) in mice fed fishmeal [28]. In sum, several amino acids as well as other nutrients, such as cholesterol and several minerals,
were enriched in fishmeal and could potentially influence metabolism.

**High-fat diets supplemented with fishmeal, salmon or beef have similar effects on adiposity**

To determine if all diets were consumed and well tolerated by the mice, we measured food intake by weighing food at multiple time points throughout this study. In average, food consumption was slightly below 3 g/mouse/day, with no difference between the dietary groups (Fig. 3a). To investigate the effects of fishmeal, salmon filet or beef consumption on body weight and adiposity, we measured body weight weekly (Fig. 3b). After the first 10 weeks on the regular HFD, the average body weight was approximately 31 g, and this increased to approximately 38 g after another 10 weeks on a HFD containing fishmeal, salmon filet or beef (Fig. 3b). There were no differences between the HFD groups in body weight gain or body weight at the end of the study, or between lean mass and fat mass measured by NMR (Fig. 3c). Feeding with fishmeal, salmon filet or beef did not influence weights of tissues and organs, such as gonadal and subcutaneous (inguinal) adipose depots, liver, spleen or kidney (Fig. 3d). Mice fed fishmeal tended to have slightly heavier livers, but this difference was only statistically significant when comparing to chow-fed mice (Fig. 3d, p = 0.12 when comparing fishmeal and salmon filet groups). As expected, several of the parameters measured above were different between the three HFD groups and the metabolically normal chow-fed group. Chow-fed mice had a lower total body weight, higher lean mass and lower fat mass (Fig. 3c), and lower adipose tissue mass, kidney and heart organ weights (Fig. 3d).

To further determine if all diets were tolerated, we measured plasma levels of markers associated with liver damage. There was no difference in plasma ALT and AST (Fig. 3e). Two mice in the fishmeal group displayed higher levels of AST or ALT, but there were no statistically significant differences between the groups. We also measured hepatic expression of genes involved in detoxification/drug metabolism (Cyp1a1, Cyp1b1), inflammation (Il1b) and hepatic fibrosis (Col1a1). There were essentially no differences in expression of these markers (Fig. 3f), except for a reduction in Cyp1a1 mRNA expression in all HFD groups.

**Fishmeal, salmon or beef consumption did not influence metabolic rates or glucose tolerance**

To assess the metabolic effects of dietary fishmeal, salmon filet or beef, all dietary groups were placed in metabolic chambers after 7 weeks on the supplemented diets (week 17). As expected, chow-fed mice had a higher energy expenditure per gram body weight, and a higher respiratory exchange ratio compared to HFD-fed mice (Fig. 4a-b). Consumption of fishmeal, salmon filet or beef did not lead to alterations in metabolic rates, and we did not observe any differences in physical activity levels (Fig. 4c).

We further investigated glucose metabolism by performing glucose tolerance testing after 9 weeks on the supplemented diets (Fig. 4d-g). Chow-fed mice had significantly lower fasting blood glucose and plasma insulin. After an i.p. injection of glucose (2 g/kg lean mass), chow-fed mice got a large increase in blood glucose, but the glucose clearance was faster compared to mice in the three HFD supplemented groups (Fig. 4f). There was no difference in glucose tolerance between mice receiving HFD supplemented with fishmeal, salmon filet or beef (Fig. 4f-g).

**High-fat feeding leads to substantial transcriptomic changes in liver**

Although the three protein sources seemed well tolerated and did not seem to affect weight gain, hepatic function and glucose clearance, they could potentially alter metabolic pathways. Thus, we measured global gene expression in liver of all four dietary groups with RNA sequencing of five representative individuals from each diet group. As expected, principal component analysis revealed a distinct gene expression pattern in chow-fed mice, while there was no separation between the HFD groups supplemented with fishmeal, salmon filet or beef (Fig. 5a). We first compared the liver transcriptome of HFD-fed mice (pooled data from fishmeal, salmon filet and beef groups) to chow-fed mice. Differential gene expression analysis was performed on 15,713 protein coding genes (Supplementary Table 4a). In total, 1818 genes were differentially expressed (fdr < 0.05), of which 341 genes were > 1.5-fold upregulated and 373 genes were > 1.5-fold downregulated (Fig. 5b).

To identify the molecular pathways that were altered with HFD feeding, we performed a gene set enrichment analysis (Fig. 5c). Several of the most enriched KEGG pathway were related to steroid or terpenoid biosynthesis and steroid biosynthesis, steroid hormone biosynthesis and terpenoid backbone biosynthesis. Many of the differentially expressed genes in these pathways are involved in cholesterol synthesis (Msmol1, Cyp51l, Nsdhl, Fdft1, Lss, Hsd17b7, Lbr, Idi1, Hmgcs1, Acat2). Furthermore, many genes belonged to the CYP family, whereof some were related to arachidonic acid or retinol metabolism. The differentially expressed genes in these pathways were downregulated in HFD-fed mice, suggesting a reduced cholesterol synthesis, and potentially reduced metabolism of steroids, arachidonic acid or retinol.

Other regulated KEGG pathways were related to inflammation and immune regulation, including the pathways for asthma, hematopoietic cell lineage, inflammatory bowel disease and Th1 and Th2 cell differentiation (Fig. 5c). Of
the specific genes were markers of T-cells or other immune cells (including \textit{Cd}4, \textit{Cd}3, \textit{Cd}28, \textit{Cd}2, \textit{Cd}22, \textit{Cd}5, \textit{Cd}6 and \textit{Cd}79), or interleukins and interleukin receptors (including \textit{il1b}, \textit{il12rb2}, \textit{il18rap}, \textit{il2rg}, \textit{il21r}, \textit{il7r} and others).

Interestingly, these genes were significantly downregulated in all groups of HFD-fed mice.

To ensure that these gene expression changes were not primarily due to either fishmeal, salmon filet or beef...
Fig. 3 Adiposity and organ weights in mice receiving a HFD supplemented with fishmeal, salmon or beef. Determination of total body weight, organ weights and hepatic toxicity in female C57BL/6 J mice fed chow or alternative HFDs containing fishmeal, salmon filet or beef (N=10 per group). Animals were terminated in week 20 (28 weeks of age) and organs were dissected. RNA isolated from liver was analysed with RT-qPCR. a Food intake for HFD groups, measured cage wise at 16 different time points expressed as grams per mouse per day. b Total body weights in HFD groups from week 0 until week 20. c Body weights, lean mass and fat mass in individual mice at 28 weeks of age (body composition was determined with minispec LF90II TD-NMR). d Organ weights for gonadal adipose tissue (AT), intraperitoneal subcutaneous AT, liver, spleen, kidney and heart at 28 weeks of age. e Plasma levels of alanine transaminase (ALT) and aspartate transaminase (AST). One blood sample from the fishmeal group was excluded due to hemolysis, and one sample was excluded from the AST graph due to technical error. f Hepatic gene expression of xenobiotic and drug metabolizing enzymes (Cyp1a1, Cyp1b1), inflammation (Il1b) and fibrosis (Coll1a1). Statistical testing was done with one-way ANOVA and Tukey’s or Dunnett’s test for multiple comparisons. *p < 0.05 between indicated groups.

consumption, we also performed differential gene expression analysis of each individual dietary group compared to the chow group (fishmeal vs. chow, salmon filet vs. chow and beef vs. chow; Supplemental Table 4b–d). We further performed gene set enrichment analysis of KEGG pathways, which revealed large overlaps between the different comparisons (Supplemental Fig. 2). Again, pathways related to steroid metabolism and the immune system were among the most enriched pathways for fishmeal, salmon filet or beef compared to chow-fed mice. These data indicate that the primary effect on hepatic gene expression was the HFD in itself, and not the alternative sources of protein.

Consumption of fishmeal leads to reduced hepatic expression of genes involved in cholesterol and steroid biosynthesis

To further investigate the hepatic effects of fishmeal, we performed differential gene analysis between the HFD groups. First we compared gene expression in livers of mice fed fishmeal and salmon filet. In total, 76 mRNAs were differentially expressed (fdr < 0.05), whereof 56 were downregulated and 6 were upregulated (fold change > 1.5) in the fishmeal group (Fig. 6a, Supplementary Table S5a). Several of the downregulated genes were involved in cholesterol or sterol biosynthesis synthesis, including the rate-limiting enzyme HMG-CoA reductase (Hmger). To identify molecular pathways that were altered, we performed a KEGG pathway overrepresentation analysis of genes that were differentially expressed with an fdr < 0.1. Again, the most downregulated pathways were related to cholesterol and steroid biosynthesis, drug metabolism as well as metabolism of other components, such as retinol, pentose/glucuronate, pyruvate or FAs (Fig. 6b).

Next, we compared gene expression in livers of mice fed fishmeal and beef (Fig. 6c). We identified 27 genes that were differentially expressed (fdr < 0.05, Supplementary Table S5b). Only two of these genes were > 1.5-fold increased (Cyp2a22, Adam11), while 20 genes were > 1.5-fold downregulated. KEGG pathways enriched among the differentially expressed genes were steroid biosynthesis, terpenoid backbone biosynthesis, propionate metabolism and pyruvate metabolism (Fig. 6d). Overall, consumption of fishmeal led to downregulation of many of the same genes and pathways when compared to either salmon filet or beef.

Lastly, we compared gene expression in livers of mice fed salmon filet and beef (Fig. 6e). Despite larger differences in FA composition between beef and salmon filet (see Table 2), only 5 protein coding genes were differentially expressed (fdr < 0.05, Supplementary Table S5c). Pdzk1ip1, Fabp5, Nfe2, Pmvk and Ngf were all upregulated in mice fed salmon filet compared to beef (FC > 1.5). This did not allow for gene set enrichment analyses. To conclude from all comparisons, steroid synthesis-related pathways in particular seemed repressed in the livers of mice receiving fishmeal.

Fishmeal consumption increased the accumulation of cholesterol in liver

Several studies have shown that both protein from fish as well as marine FAs can modify circulating lipids and metabolism of lipids in liver [14]. Our discovery of a likely repression of the steroid and cholesterol biosynthesis pathways in mice receiving fishmeal, prompted us to follow up with detailed analysis of circulating and hepatic lipids. As expected, feeding with all HFDs increased plasma concentrations of triglycerides, total cholesterol, HDL cholesterol as well as LDL and VLDL cholesterol (Fig. 7a–b). Similarly, high-fat feeding also increased hepatic levels of triglycerides and total cholesterol, as compared to chow-fed mice (Fig. 7c). Levels were similar between the HFD groups, but interestingly, mice fed fishmeal had higher levels of hepatic cholesterol (Fig. 7c) as compared to mice fed salmon filet (35% increase, p = 0.002) or beef (36% increase, p = 0.002). Dietary fishmeal also tended to increase the concentration of plasma cholesterol (Fig. 7a) as compared to salmon filet (unadjusted p = 0.029, not significant after adjustment for multiple testing).

To investigate if hepatic alterations in cholesterol levels were reflected in altered bile acid concentrations, we measured total bile acids in plasma, liver and faeces. Plasma bile acid concentrations were highly variable, and there were no significant differences in bile acids between the groups (Fig. 7d). No differences were observed in bile acid concentration in livers among the groups; however, feeding with HFD increased the concentration of bile acids in faeces as compared to feeding with chow.
High cholesterol content in fishmeal results in hepatic repression of cholesterol metabolism

To further investigate why mice receiving fishmeal had elevated hepatic cholesterol, we analysed expression of genes important for hepatic cholesterol uptake, synthesis and excretion. RT-qPCR analysis with all individuals included per group (n = 10) also functioned to verify our transcriptomic analyses that identified several genes in the cholesterol and sterol biosynthesis pathways as repressed in fishmeal compared to salmon filet or beef (see Fig. 8a). Both Hmgcr and Fdps, which are involved in cholesterol and sterol biosynthesis, were downregulated in fishmeal compared to salmon filet-fed mice (Fig. 8a). Pcsk9, an important regulator of LDL receptor degradation, was also downregulated in mice fed fishmeal compared to salmon. Interestingly, while HFD seemed to suppress expression of hepatic genes involved in cholesterol uptake and synthesis, the effect was stronger when the diet was substituted with fishmeal compared to salmon filet.

Next, we measured expression of transcription factors known to stimulate cholesterol synthesis (Srebf2) and lipogenesis (Srebf1c and Mlxipl/Chrebp), and transcription factors that are activated when cholesterol metabolites...
accumulates in liver (Nr1h3/LXRα and Nr1h2/LXRβ) to stimulate hepatic removal of cholesterol by activating the cholesterol efflux transporters (Abca1 and Abcg1) and the rate-limiting enzyme in bile acid synthesis (Cyp7a1). Several of these genes were differently expressed between chow and the HFD groups, but no differences in expression were observed between the fishmeal, salmon filet and beef groups (Fig. 8b–c).

Based on our gene expression analysis, we centred our attention on hepatic uptake of LDL, since several genes in this process were expressed at lower levels in the fishmeal group compared to salmon filet. Plasma levels of the Pcsk9 protein, as well as hepatic expression of Pcsk9 protein, were lower in fishmeal compared to the chow or salmon filet groups (Fig. 8d–f). Hepatic protein expression of Ldlr was similarly elevated in all HFD groups compared to chow, whereas protein expression of Hmgcr was similar in all groups. Although these analyses are insufficient to give a clear explanation for the observed higher content of hepatic cholesterol with fishmeal, it suggests that fishmeal represses Pcsk9 expression, which in turn may affect hepatic Ldlr recycling and/or hepatic cholesterol uptake.

**Discussion**

In this study, we used mice to investigate metabolic effects of dietary intake of protein from salmon fishmeal and two protein sources that are traditionally used in the human
diet. Custom-made HFDs, with half of the dietary protein from fishmeal, salmon filet or beef, were given obese and glucose intolerant female mice. These mice were compared to reference mice given a standard rodent chow diet. All HFDs seemed well tolerated, based on equal consumption of food, animal growth curves, energy substrate oxidation, glucose tolerance, plasma lipids and markers of hepatic toxicity. Still, mice fed fishmeal had alterations in the hepatic transcriptome and increased liver cholesterol, which was accompanied by a tendency for increased liver weight and plasma cholesterol. Thus, we concentrated our molecular analysis on dissecting changes in hepatic cholesterol metabolism and pathways involved.

The high-fat diets were isocaloric and adjusted to contain equal amounts of carbohydrates, protein and fat. Still, detailed analysis of the protein supplements revealed differences in amino acid composition, certain vitamins and minerals, FA saturation and cholesterol content. The source of dietary proteins may influence metabolism by differences in amino acid content and bioactive peptides [3, 14, 29]. Fishmeal contained high levels of glycine, proline and hydroxyproline compared to salmon filet and beef, probably...
due to a high collagen content. None of these are essential amino acids. Collagen peptides are reported to have antioxidant properties as well as angiotensin I-converting enzyme inhibitory properties [3], while supplementation with glycine may improve glucose tolerance in humans and rodents [30]. Our transcriptomic analysis revealed no clear differences in hepatic expression of genes in antioxidant signalling pathways, and glucose clearance was similar between the three diets.

With respect to vitamins and minerals, fishmeal contained high levels of vitamin B₁₂, copper, zinc, calcium and iodine. These nutrients are not suspected to alter hepatic cholesterol levels, but particularly for copper, the high levels resulted in intake above recommended
levels for human consumption (normalized to mg/kg body weight). The Nordic Nutrition Recommendations from 2012 recommend an upper intake level of 5 mg copper pr. day [28], which for an adult human will be reached with a daily intake of 58 g of fishmeal. We did not observe any sign of copper toxicity with this diet for 10 weeks, but the high content of zinc may have functioned as a chelating agent and prevented copper uptake [31]. Nevertheless, the high content of several nutrients in fishmeal must be considered if salmon fishmeal is to be used as an ingredient in food for human consumption.

With respect to the FA composition, freeze-dried fishmeal and salmon filet contained low levels of SFA compared to beef. Fishmeal also contained higher levels of certain marine PUFAs (EPA and DHA) compared to beef, but levels were low compared to salmon filet. Studies in rodents have shown that intake of omega FAs can increase, while intake of saturated FAs can decrease insulin sensitivity [32]. We observed no differences
in glucose uptake in our study, as assessed by GTT, suggesting that all diets affected insulin signalling similarly. PUFAs may further signal to influence lipid metabolism and inflammation [7–9], and prevent hepatic cholesterol accumulation [33]. Interestingly, the observed hepatic cholesterol levels in our study are in line with effects mediated by differences in PUFA content between freeze-dried fishmeal and salmon filet, but not when compared to beef, suggesting that levels of PUFA alone cannot explain increased cholesterol accumulation with fishmeal. Importantly, all three diets contained high levels of SFA from lard, which may mask a potential metabolic response caused by differences in PUFAs present at low levels.

In addition to differences in FAs, cholesterol content was higher in freeze-dried fishmeal compared to salmon filet and beef, resulting in 0.11% versus ~0.05% cholesterol in higher in freeze-dried fishmeal compared to salmon filet, but not when compared to beef, suggesting that levels of PUFA alone cannot explain increased cholesterol accumulation with fishmeal. Importantly, all three diets contained high levels of SFA from lard, which may mask a potential metabolic response caused by differences in PUFAs present at low levels.

Dietary supplementation with a modest dose of fishmeal (7.5 g/d) for 8 weeks was well tolerated but did not influence cardiometabolic health markers or glucose clearance compared to placebo [20]. Since human trials examining health effects of lean and fatty fish protein supplements given at modest doses have variable results, a main objective of this rodent study was to investigate health effects with high intake of fishmeal. We did not observe differences in glucose clearance in obese mice with high intake (half of the protein) from fishmeal, salmon filet or beef. Our results in mice contrast several previous studies in rodents that have indicated positive metabolic health effects of lean and fatty fish protein supplements given at modest doses have variable results. We recently tested the fishmeal used in this study in a randomized trial on pre-diabetic human participants [20]. Collectively, these rodent studies suggest that not only marine FAs but also fish proteins mediate the beneficial health effects of fish. It is not clear why we are unable to replicate the above findings, but our study was designed differently. Our diet intervention started in obese mice, enabling us to circumvent effects on development of adiposity, with different beneficial health effects of fish. It is not clear why we are unable to replicate the above findings, but our study was designed differently. Our diet intervention started in obese mice, enabling us to circumvent effects on development of adiposity, with differences in body weight as a mediator of effectiveness on glucose clearance. Furthermore, food consists of many different macro- and micronutrients that may potentially signal independently of the tested ingredients, in our case proteins. Our carefully designed isocaloric diets, resulting in equal energy consumption of energy substrates (carbohydrates, protein and fat) and may have limited several confounding factors not necessarily accounted for in previous rodent studies.
In conclusion, our study reveals no sign of toxicity of fishmeal in mice, when constituting 50% of total dietary protein, but results in a significant rise in hepatic cholesterol. The biological mechanism behind the elevated hepatic cholesterol should be dissected further before fishmeal is used for human consumption. Lastly, industrial production of fishmeal with lower levels of cholesterol and certain minerals may be necessary before salmon by-products can be endorsed as a dietary component suitable for human consumption at higher doses.

Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s00394-022-02930-y.

Acknowledgements  The authors are grateful to engineers Ingunn Jermstad and Shasta Khan at the Norwegian Transgenic Centre for technical assistance and members of the Dalen laboratory and the Molecular Nutrition Unit at the Department of Nutrition for scientific discussions.

Author contributions  M.H., K.T.D., K.B.H., S.M.U. and T.S contributed to conceptualization. M.H. and A.D performed data curation. M.H., A.D. and K.T.D did formal analysis. K.T.D., K.B.H., S.M.U. and T.S were involved in funding acquisition. M.H., A.D. and F.N contributed to investigation. M.H., K.T.D. and T.S were involved in project administration. K.T.D. and T.S contributed to resources. K.T.D performed supervision and validation. M.H. and A.D contributed to visualization. M.H. and K.T.D were involved in roles/writing – original draft. M.H., A.D., F.N., S.M.U., K.H., T.S. and K.T.D were involved in writing – review & editing.

Funding  Open access funding provided by University of Oslo (incl Oslo University Hospital). This study received financial support from the University of Oslo and FHF—Norwegian Seafood Research Fund, Oslo, Norway. The funding body was not involved in the design of the study or in the collection, analysis and interpretation of data, nor in writing the manuscript.

Data availability and materials  Gene expression data described in this study are available in the NCBI GEO repository (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE188546, accession number GSE188546). Remaining data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations  Conflict of interest  The authors have no conflicts of interest. During the past 5 years, S.M.U. has received research grants from Mills DA, TINE BA and Olympic Seafood, none of which are related to the content of this manuscript. During the past 5 years, K.B.H. has received research grants or honoraria from Mills DA, TINE BA, Olympic Seafood, Amgen, Sanofi and Pronova, none of which are related to the content of this manuscript.

Ethics approval  Experimental use of animals was approved by the Norwegian Animal Research Authority (Mattilsynet, approvals FOTS id: #10902), and conformed to the ARRIVE guidelines and ethical guidelines in the Norwegian (FOR-2015-06-18-761) and European Parliament (Directive 2010/63/EU) regulations on protection of animals used for scientific purposes.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Food and Agriculture Organization (2017) The future of food and agriculture – Trends and challenges. Rome
2. Caruso G, Floris R, Serangeli C, Di Paola L (2020) Fishery wastes as a yet undiscovered treasure from the sea: biomolecules sources, extraction methods and valorization. Marine Drugs 18(12):622
3. Coppola D, Lauritano C, Palma Esposito F, Riccio G, Rizzo C, de Pascale D (2021) Fish waste: from problem to valuable resource. Mar Drugs 19(2):116
4. Magnus Myhre RR, Nystøyl R, Strandheim G (2019) Analyse marint restråstoff 2019. SINTEF Ocean AS Report 2020:00904
5. Torris C, Molin M, Cvanacorova MS (2016) Lean fish consumption is associated with lower risk of metabolic syndrome: a Norwegian cross sectional study. BMC Public Health 16(1):347. https://doi.org/10.1186/s12889-016-3014-0
6. Torris C, Smastuen MC, Molin M (2018) Nutrients in fish and possible associations with cardiovascular disease risk factors in metabolic syndrome. Nutrients. https://doi.org/10.3390/nu10070952
7. Calder PC (2020) n-3 PUFA and inflammation: from membrane to nucleus and from bench to bedside. Proc Nutr Soc 79(4):404–416. https://doi.org/10.1017/S0029665120007077
8. Jump DB (2008) N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol 19(3):242–247. https://doi.org/10.1097/MOL.0b013e3282faffa6
9. Rodriguez-Cruz M, Serna DS (2017) Nutrigenomics of ω-3 fatty acids: Regulators of the master transcription factors. Nutrition 41:90–96. https://doi.org/10.1016/j.nut.2017.04.012
10. Levine Morgan E, Suarez Jorge A, Brandhorst S, Balasubramanian P, Cheng C-W, Madia F, Fontana L, Mirisola Mario G, Guevara-Aguirre J, Wan J, Passarino G, Kennedy Brian K, Wei M, Cohen P, Crimmins Eileen M, Longo Valter D (2014) Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab 19(3):407–417. https://doi.org/10.1016/j.cmet.2014.02.006
11. Chalvon-Demersay T, Azzout-Marniche D, Arfsten J, Egli L, Gaudichon C, Karagounis LG, Tomé D (2017) A systematic review of the effects of plant compared with animal protein sources on features of metabolic syndrome. J Nutr 147(3):281–292. https://doi.org/10.3945/jn.116.239574
12. Song M, Fung TT, Hu FB, Willett WC, Longo BD, Chan AT, Giovannucci EL (2016) Association of animal and plant protein intake with all-cause and cause-specific mortality. JAMA Intern Med 176(10):1453–1463. https://doi.org/10.1001/jamainternmed.2016.4182
13. Mittendorfer B, Klein S, Fontana L (2020) A word of caution against excessive protein intake. Nat Rev Endocrinol 16(1):59–66. https://doi.org/10.1038/s41574-019-0274-7

14. Dale HF, Madsen L, Lied GA (2019) Fish–derived proteins and their potential to improve human health. Nutr Rev 77(8):572–583. https://doi.org/10.1093/nutrit/nuz016/NutritionReviews

15. Ouellet V, Marois J, Weisnagel SJ, Jacques H (2007) Dietary cod protein improves insulin sensitivity in insulin-resistant men and women. A randomized controlled trial. Diabet Care 30(11):2816–2821. https://doi.org/10.2337/dc07-0273

16. Viksøren LA, Nygård OK, Lied E, Rostrup E, Gudbrandsen OA (2013) A randomized study on the effects of fish protein supplement on glucose tolerance, lipids and body composition in overweight adults. Br J Nutr 109(4):648–657. https://doi.org/10.1017/S0007114512001717

17. Pilon G, Ruzzin J, Rioux L-E, Lavigne C, White PJ, Frøyland L, Jacques H, Bryl P, Beaulieu L, Marette AJM (2011) Differential effects of various fish proteins in altering body weight, adiposity, inflammatory status, and insulin sensitivity in high-fat–fed rats. Metabolism 60(8):1122–1130

18. Wergedahl L, Liaset B, Gudbrandsen OA, Lied E, Espe M, Muna Z, Mørk S, Berge RKJ, 2004) Fish protein hydrolysate reduces plasma total cholesterol, increases the proportion of HDL cholesterol, and lowers acyl-CoA: cholesterol acyltransferase activity in liver of Zucker rats. J Nutr 134(6):1320–1327

19. Drotningsvik A, Mørk S, Berge RK, Bjørndal BJF, 2011) Three differently generated salmon protein hydrolysates reveal opposite effects on glucose regulation and markers of insulin sensitivity in high-fat-fed rats. Am J Physiol Endocrinol Metabol 314(3):E251–E265. https://doi.org/10.1152/ajpendo.00337.2017

20. Hustad KS, Ottestad I, Hjorth M, Dalen KT, Sæther T, Sheikh NA, Vaage J, Kimmel AR, Dalen KT (2021) Plin2 deletion increases inflammatory status, and insulin sensitivity in high-fat–fed rats. Metabolism 60(8):1122–1130

21. Li Y, Khanal P, Norheim F, Bjellaa T, Drevon CA, Vaage J, Kimmel AR, Dalen KT (2021) Plin2 deletion increases cholesterol ester lipid droplet content and disturbs cholesterol balance in adrenal cortex. J Lipid Res 62:100048. https://doi.org/10.1194/jlr.R1.2021.100048

22. Bushnell B BBMap. sourceforge.net/projects/bbmap/

23. Kim D, Paggi JM, Park C, Bennett C, Salzberg SL (2019) Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol 37(8):907–915. https://doi.org/10.1038/s41578-019-0201-4

24. Liao Y, Smyth GK, Shi W (2014) featureCounts: an efficient geneprofile program for assigning sequence reads to genomic features. Bioinformatics 30(7):923–930. https://doi.org/10.1093/bioinformatics/btt656

25. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550. https://doi.org/10.1186/s13059-014-0550-8

26. Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16(5):284–287. https://doi.org/10.1089/omi.2011.0118

27. Norwegian Food Composition Database (2020) www.matvaretabellen.no.

28. Nordic Council of Ministers (2012) Nordic. Nutr Recomm. https://doi.org/10.6027/Nord2014-002

29. Da Rocha M, Alemán A, Baccan GC, López-Caballero ME, Gómez-Guilén C, Montero P, Prentice C (2018) Anti-inflammatory, antioxidant, and antimicrobial effects of underutilized fish protein hydrolysate. J Aquat Food Prod Technol 27(5):592–608. https://doi.org/10.1080/10498850.2018.1461160

30. Alves A, Bassot A, Bulteau A-L, Pirola L, Morio B (2019) Glycine metabolism and its alterations in obesity and metabolic diseases. Nutrients 11(6):1356

31. Kodama H, Fujisawa C, Bhadhpratis W (2012) Inherited coping transport disorders: biochemical mechanisms, diagnosis, and treatment. Curr Drug Metab 13(3):237–250. https://doi.org/10.2174/187220121399302045

32. Small L, Brandon AE, Turner N, Cooney GJ (2018) Modeling insulin resistance in rodents by alterations in diet: what have high-fat and high-calorie diets revealed? Am J Physiol Endocrinol Metabol 314(3):E251–E265. https://doi.org/10.1152/ajpendo.00337.2017

33. Hayashi Y, Lee-Okada HC, Nakamura E, Tada N, Yokomizo T, Fujiwara Y, Ichi I (2021) Ablation of fatty acid desaturase 2 (FADS2) exacerbates hepatic triacylglycerol and cholesterol accumulation in polysaturated fatty acid-depleted mice. FEBS Lett 595(14):1920–1932. https://doi.org/10.1002/1873-3468.14134

34. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ (1998) Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93(5):693–704. https://doi.org/10.1016/S0092-8674(00)81432-4

35. Acston S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M (1996) Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271(5248):518–520. https://doi.org/10.1126/science.271.5248.518

36. Rohlmann A, Gotthardt M, Hammer RE, Herz J (1998) Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 101(3):689–695. https://doi.org/10.1172/jci1240

37. Warden BA, Fazio S, Shapiro MD (2020) The PCSK9 revolution: Current status, controversies, and future directions. Trends Cardiovasc Med 30(3):179–185. https://doi.org/10.1016/j.tcm.2019.05.007

38. Hovland IH, Leikanger IS, Stokkeland O, Waage KH, Mjøs SA, Brokstad KA, McCann A, Ueland PM, Slizyte R, Carvajal A (2019) Effects of low doses of fish and milk proteins on glucose regulation and markers of insulin sensitivity in overweight adults: A randomised, double blind study. Eur J Nutr

39. Lavigne C, Tremblay F, Asselin G, Jacques H, Marette AJAJoP-E, Rioux L-E, Lavigne C, Tremblay F, Asselin G, Jacques H, Marette AJAJoP-E (2019) Effects of low doses of fish and milk proteins on glucose regulation and markers of insulin sensitivity in overweight adults: What have high-fat and high-calorie diets revealed? Am J Physiol Endocrinol Metabol 314(3):E251–E265. https://doi.org/10.1152/ajpendo.00337.2017

40. Lee EJ, Hur J, Ham SA, Jo Y, Lee S, Choi MJ-J, Seo HG (2017) Fish collagen peptide inhibits the adipogenic differentiation of 3T3-L1 pre-adipocytes and ameliorates obesity in high fat diet-fed mice. Int J Biol Macromol 2174/13892001279932045

41. Holm JB, Rønnevik A, Tastesen HS, Fjære E, Fauske KR, Liisberg U, Madsen L, Kristiansen K, Liaset B (2016) Diet-induced obesity, energy metabolism and gut microbiota in C57BL/6j mice fed Western diets based on lean seafood or lean meat mixtures. J Nutr Biochem 31:127–136. https://doi.org/10.1016/j.jnutbio.2015.12.017